4.0 Article

Ocular phenotype and therapeutic interventions in keratitis-ichthyosis-deafness (KID) syndrome

Journal

OPHTHALMIC GENETICS
Volume -, Issue -, Pages -

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/13816810.2023.2258218

Keywords

Keratitis-ichthyosis-deafness syndrome; ectodermal dysplasia; GJB2; ocular manifestations

Ask authors/readers for more resources

This study reports the ocular manifestations, clinical course, and therapeutic management of patients with keratitis-ichthyosis-deafness syndrome. Four patients were recruited for examination and mutational analysis. The main ophthalmic features included keratopathy, ocular surface disease, and corneal stromal scarring. Oral therapy with ketoconazole was found to stabilize the corneal and skin disease.
Background: To report ocular manifestations, clinical course, and therapeutic management of patients with molecular genetically confirmed keratitis-ichthyosis-deafness syndrome.Methods: Four patients, aged 19 to 46, with keratitis-ichthyosis-deafness syndrome from across the UK were recruited for a general and ocular examination and GJB2 (Cx26) mutational analysis. The ocular examination included best-corrected visual acuity, slit-lamp bio-microscopy, and ocular surface assessment. Mutational analysis of the coding region of GJB2 (Cx26) was performed by bidirectional Sanger sequencing.Results: All four individuals had the characteristic systemic features of keratitis-ichthyosis-deafness syndrome. Each patient was found to have a missense mutation, resulting in the substitution of aspartic acid with asparagine at codon 50 (p.D50N). Main ophthalmic features were vascularizing keratopathy, ocular surface disease, hyperkeratotic lid lesions, recurrent epithelial defects, and corneal stromal scarring. One patient had multiple surgical procedures, including superficial keratectomies and lamellar keratoplasty, which failed to prevent severe visual loss. In contrast, oral therapy with ketoconazole stabilized the corneal and skin disease in two other patients with keratitis-ichthyosis-deafness syndrome. The patient who underwent intracorneal bevacizumab injection showed a marked reduction in corneal vascularization following a single application.Conclusions: Keratitis-ichthyosis-deafness syndrome is a rare ectodermal dysplasia caused by heterozygous mutations in GJB2 (Cx26) with a severe, progressive vascularizing keratopathy. Oral ketoconazole therapy may offer benefit in stabilizing the corneal and skin disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available